Non-Muscle Invasive Bladder Cancer Resistant to Bcg
Küçük Resim Yok
Tarih
2013
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Iniestares, S.A.
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
Treatment options for patients with non-muscle invasive bladder cancer (NM/BC) refractory to intravesical bacillus Calmette-Guerin (BCG) therapy is reviewed in this article based on the recent published literature. Although intravesical BCG is the best bladder sparing treatment option for NM/BC to prevent recurrence and progression, about 1/3 of cases are refractory to this treatment. At this point radical cystectomy is the standard treatment of choice. If this option is not feasible, intravesical chemotherapy with docetaxel or gemcitabine, the combination of BCG and interferon (INF)-alpha or device-assisted intravesical strategies, such as mitomycin-EMDA or chemohyperthermia are some of the candidates for further treatment.
Açıklama
Anahtar Kelimeler
Non-muscle invasive bladder cancer, BCG failure, Itravesical therapy, Bacillus-Calmette-Guerin, Transitional-Cell Carcinoma, Phase-Ii Trial, Mitomycin-C, Radical Cystectomy, Intravesical Chemotherapy, Electromotive Mitomycin, 5-Aminolevulinic Acid, Urothelial Carcinoma, Plus Interferon
Kaynak
Archivos Espanoles De Urologia
WoS Q Değeri
N/A
Scopus Q Değeri
Cilt
66
Sayı
9